Arbor Trust Wealth Advisors LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Arbor Trust Wealth Advisors LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 394 shares of the medical research company’s stock, valued at approximately $209,000.

Other hedge funds have also modified their holdings of the company. WCM Investment Management LLC lifted its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after acquiring an additional 2,928 shares in the last quarter. Phoenix Holdings Ltd. lifted its stake in Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after acquiring an additional 1,654 shares in the last quarter. DMC Group LLC lifted its stake in Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after acquiring an additional 84 shares in the last quarter. S. R. Schill & Associates lifted its stake in Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after acquiring an additional 792 shares in the last quarter. Finally, Check Capital Management Inc. CA purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $219,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

TMO traded down $3.22 during midday trading on Tuesday, reaching $554.65. The company’s stock had a trading volume of 1,010,297 shares, compared to its average volume of 1,539,256. The stock has a market cap of $211.72 billion, a P/E ratio of 35.90, a PEG ratio of 2.38 and a beta of 0.80. The company has a fifty day simple moving average of $571.79 and a 200 day simple moving average of $526.53. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter last year, the company earned $5.40 EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis. Research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last 90 days. 0.32% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TMO shares. HSBC started coverage on Thermo Fisher Scientific in a research note on Monday, December 18th. They set a “buy” rating and a $610.00 price target for the company. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $601.56.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.